Several studies have reported that a high-expression ratio of HOXB13 to IL17BR predicts tumor recurrence in node-negative, estrogen receptor (ER) α-positive breast cancer patients treated with tamoxifen. The molecular mechanisms underlying this dysregulation of gene expression remain to be explored. Our epigenetic analysis has found that increased promoter methylation of one of these genes, HOXB13, correlate with the decreased expression of its transcript in breast cancer cell lines (p < 0.005).
Introduction
Breast tumorigenesis and cancer progression are directly related to the effects of the hormone estrogen [1] . Tamoxifen, an anti-estrogen, is a widely used in the treatment of hormone-dependent breast cancers, but up to 40% of estrogen receptor alpha (ERα)-positive breast cancer patients fail to respond or develop resistance to the drug.
Intensive efforts have been undertaken to identify molecular biomarkers for predicting response (or resistance) to anti-estrogen treatment. Recent reports identify a two-gene expression ratio HOXB13:IL17BR, derived from a genome-wide microarray analysis of ERα-positive breast tumors that is prognostic for disease-free and/or relapse-free survival in lymph node-negative patients receiving tamoxifen [2] [3] [4] [5] .
The HOXB13 gene is related to a large Homeobox superfamily whose members take part in establishing cell fate and identity throughout embryonic development. This group of genes also plays an important role in maintaining cellular homeostasis in adult cells [6] . Alterations of Homeobox gene expression have been identified in many solid tumors including cancers of the endometrium, cervix, ovary, and prostate that overexpress HOXB13 [7] [8] [9] [10] . For Hoxb13, mice homozygous for its functional mutation show overgrowth in all major structures derived from the tail bud [11] . Furthermore, over-expressed HOXB13 is a pro-proliferative modulator of ovarian cancer cell growth and may play a role in the development of tamoxifen resistance in patients with ERα-positive ovarian cancer [12] . In contrast, the gene is subject to epigenetic control and may function as a tumor suppressor in renal cell carcinoma and melanoma [13, 14] .
Because loss of HOXB13 may lead to a deregulation of cellular processes that promote neoplasia and its expression is undetectable in 41% of ERα-positive tumors [5] , we hypothesize that this gene may be epigenetically repressed in a subset of breast cancers and that detection of its methylation may have a prognostic value. Herein, we report that the HOXB13 promoter CpG island is frequently hypermethylated in ERα-positive breast tumors and cell lines. Further analysis confirms that HOXB13 is an ERα-responsive gene and suggests its over-expression may be the result of tamoxifen's modulation on estrogen signaling. In addition, hypermethylation of HOXB13 may be an adverse prognostic factor in ERα-positive cancer patients.
Materials and Methods
Reagents and antibodies. 17β-estradiol (E2), 4-hydroxy-tamoxifen (4-OHT), and 5-aza-2'-deoxycytidine (DAC) were purchased from Sigma (St. Louis, MO). Culture media and fetal bovine serum (FBS) were obtained from Invitrogen (Carlsbad, CA). The monoclonal HOXB13 and β-Actin antibodies used in western blotting were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Clinical samples and cell lines. Frozen tissues were collected by the Tissue
Procurement Service in accordance with the protocols approved by the Institutional Review Board of the Ohio State University. Clinical and pathological data, including age at surgery, lymph node status, estrogen receptor (ER) status, progesterone receptor (PR) status, lymphovascular invasion, the presence of ductal carcinoma in situ (DCIS) component, tumor grade, and tumor size were collected from pathology reports. Clinical follow up data were available for 57 ERα-positive breast cancer patients. The time in months from the definitive breast surgery until the last known disease-free follow-up or first cancer recurrence were collected. Genomic DNAs were isolated from tissues with the QIAmp DNA mini kit according to manufacturer's protocol (Qiagen, Valencia, CA).
Genomic DNAs for 38 breast cancer cell lines were obtained from the laboratory of Dr.
Joe Gray at the Lawrence Berkeley National Laboratory, Berkeley.
Cell culture. MCF7
T breast cancer cell line was maintained in MEM with 2 mM Lglutamine, 0.1 mM non-essential amino acids, 50 units/mL penicillin, 50 μg/mL streptomycin, 6 ng/mL insulin, and 10% FBS. T47D cells were maintained in RPMI 1640 with 2 mM L-glutamine, 50 units/mL penicillin, 50 μg/mL streptomycin, 6 ng/mL insulin, Reverse transcription reactions were performed with Oligo dT using Superscript III (Invitrogen). RT-PCR primers for HOXB13 were designed using Oligo v6.59 (Molecular Biology Insights, Cascade, CO) and are available by request. Primers for the reference gene TATA Binding Protein (TBP) were previously described [17] . qRT-PCR was performed using Power SYBR Green master mix (Applied Biosystems, Foster City, CA).
Expression copy-number was determined by six-point absolute standard curves (125,000 to 40 copies) of cloned PCR products. All PCR reactions were assayed in triplicate and included melting curve analysis. Reactions were performed on an ABI 7500 (Applied Biosystems, Foster City, CA).
Immunoblotting. After exposing to E2 ( were generated using the Kaplan-Meier method, and a log-rank test was used to test for differences. and a recent study [20] implicate that the methylation-associated silencing of HOXB13 may be regulated in an ERα-dependent manner. We therefore investigated the effects of estrogen on the expression of HOXB13 in the MCF7 H cell line, which is independent of that (MCF7 T ) routinely analyzed in our laboratory. It was initially chosen because a low level of HOXB13 expression was detected, despite the presence of moderate methylation. We treated hormone-deprived MCF7 H cells with 10 nM E2 and measured its HOXB13 mRNA level by qRT-PCR ( Figure 3A) . No effect was observed after 30 min of E2 treatment (data not shown). After 3 hr, estrogen repressed HOXB13 expression 1.75-fold (p < 0.005). Next, we used a second cell line, T47D, for more detailed studies because HOXB13 was partially methylated and expressed at higher levels than that of MCF7 H ( Figure 2D ). Similarly, hormone-deprived T47D cells were treated with 10 nM E2, and HOXB13 expression was measured by both qRT-PCR and Western blotting.
Results

Hypermethylation of the
The results showed significant estrogen-induced changes in HOXB13 mRNA levels, increasing after 30 min of the treatment (p < 0.005) and decreasing below the control after 3 hr (p < 0.05)( Figure 3B ). We also observed a similar trend in estrogen's effect on HOXB13 protein expression ( Figure 3C ). In support of our evidence that it is an estrogen-responsive gene, bioinformatics analysis identified a potential ERα cisregulatory region upstream of the HOXB13 transcriptional start site (Supplementary   Table SI) . Interestingly, treatment with 4-OHT abrogated the ability of E2 to repress HOXB13 expression in T47D cells; as a result of this de-repression, its mRNA levels steadily increased over a 24-hr period ( Figure 3D ).
Hypermethylation of the HOXB13 promoter CpG island frequently occurs in
ERα-positive breast tumors. To determine whether promoter hypermethylation of HOXB13 occurred in vivo, we performed qMSP in 120 primary breast tumors (Supplementary Table SII 
Hypermethylation of HOXB13 is associated with poor disease-free survival (DFS) in ERα-positive breast cancer patients. We used Cox proportional-hazard
analysis to test for a relationship between hypermethylation of HOXB13 and clinical outcome in 57 of the ERα-positive patients (Table II) . In univariate analysis, hypermethylation of HOXB13 was significantly associated with poor DFS (HR=3.25, 95% CI 1.13 to 9.37; p = 0.029). As expected, tumor size, lymph node metastasis, and PR status were each associated with DFS (Table II) .
In conjunction with the methylation status of HOXB13, tumor sizes greater than 5 cm were associated with poor DFS (HR=4.43, 95% CI 1.18 to 16.62; p = 0.027) as was PR negative status (HR=0.26, 95% CI 0.07 to 0.91; p = 0.035) (Table II) . After controlling for PR status, hypermethylation of HOXB13 remained significantly associated with poor DFS (HR=4.01, 95% CI 1.16 to 13.38; p = 0.028). The sample size was insufficient to provide a power of 80% for models including greater than two patient covariates. The predictive value of HOXB13 hypermethylation for DFS was visualized by Kaplan-Meier curve ( Figure 4C ).
Discussion
The present finding supports a recent study by Wang et al. [20] We demonstrated that administration of 4-OHT abolished E2-mediated repression in T47D cells and actually led to a sustained induction of HOXB13 expression (see Figure 3D ). That transcriptional induction of HOXB13 occurs with exposure to both estrogen and 4-OHT may provide a biological explanation for the propensity for aberrant HOXB13 expression in many ERα-positive breast cancer patients undergoing tamoxifen therapy. As we discussed earlier, over-expressed HOXB13 may disrupt cellular homeostasis, resulting in further promotion of tumor cell proliferation [12] . Therefore, this aberrant up-regulation could partially account for the high-expression ratio of HOXB13 to IL17BR observed in ERα-positive breast cancer patients who develop subsequent tamoxifen resistance [2] [3] [4] [5] .
Our further analysis suggests that epigenetic mechanisms play a role in this estrogen-mediated repression. Increased density of methylation in the HOXB13
promoter CpG island correlate with the reduction of gene expression in ERα-positive breast cancer cells (see Figure 2D) . In a scenario with persistent activation of estrogen signaling, DNA methyltransferases and other epigenetic components are recruited to methylate CpG sites within the HOXB13 promoter CpG island, leading to permanent gene silencing [13, 14] .This epigenetic effect is also a potential mechanism for the absence of HOXB13 expression in vivo. In a large clinical study of 1,252 primary tumors, HOXB13 expression was undetectable in 41% of ERα-positive tumors [5] .
These results are consistent with the current study showing that HOXB13 hypermethylation occurs in 38% of ERα-positive tumors ( Figure 4A ).
Because this study investigated HOXB13 only as an epigenetic marker in patients, its findings must be interpreted separately from four HOXB13:IL17BR expression ratio studies primarily for early-stage, node-negative, and ERα-positive patients [2] [3] [4] [5] .
Compared with these four cohorts, our studied population has a lower percentage of both node-negative patients and tumors ≤ 2 cm while at the same time a higher percentage of patients with 3 positive lymph nodes and tumors >5 cm. In addition, nearly half of our studied tumors are poorly differentiated. The multivariate models (Table I) indicate that HOXB13 hypermethylation correlates with established predictors of poor prognosis such as PR negative status [24, 25] , increasing lymph node metastases [26, 27] , and increasing tumor sizes [28, 29] . This hypermethylation is also associated with poor DFS in ERα-positive breast cancer patients ( Figure 4C ). The relatively small sample size makes the 95% CI surrounding the point estimates of both the odds and hazard ratios large (see Tables I & II) . This sample size limits our ability to construct more comprehensive models for Cox proportion hazard analysis. However, suggested by these data, the robustness of HOXB13 hypermethylation as a potential prognostic factor merits future investigation in a large cohort.
In ERα-positive breast cancer patients. Kaplan-Meier curves were plotted based on methylation status (PMR > 4%). HR, hazard ratio; CI, 95% confidence interval.
